sellModerate
Gilde Healthcare U.A. Cooperatieve IV sold $4.2M of LVTX
owner at LAVA Therapeutics NV. 2,871,370 shares at an average of $1.47, traded Oct 20, 2015, filed Oct 20, 2025.
Warning score
57Value
$4.2M
2,871,370 shares
Holdings after
2,947,781
-97% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +12Role10% owner
- +25Trade size$4.2M at market
- +20Share of holdings soldSold 97% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001193125-25-243899, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 16, 2025 | SOpen-market sale Common Shares | -690,239 | $1.49 | $1.0M | 4,128,912 | Oct 20, 2025 |
| Oct 17, 2025 | SOpen-market sale Common Shares | -1,181,131 | $1.47 | $1.7M | 2,947,781 | Oct 20, 2025 |
| Oct 20, 2015 | SOpen-market sale Common Shares | -1,000,000 | $1.46 | $1.5M | 1,947,781 | Oct 20, 2025 |
Related signals
Other insiders at LAVA Therapeutics NV and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 33Weak | LVTXsell LAVA Therapeutics NV | Gilde Healthcare U.A. Cooperatieve IV owner | $719k 475,027 shares | -9% | |
| 24Weak | LVTXsell LAVA Therapeutics NV | Gilde Healthcare U.A. Cooperatieve IV owner | $198k 126,992 shares | -2% | |
| 57Moderate | LVTXsell LAVA Therapeutics NV | Versant Venture Capital VI, L.P. owner | $4.1M 2,903,403 shares | -122% | |
| 47Moderate | LVTXsell LAVA Therapeutics NV | Versant Venture Capital VI, L.P. owner | $2.5M 1,684,434 shares | -49% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.